Translational biomarkers: from discovery and development to clinical practice
Related Experiment Video
Updated: Mar 10, 2026

Quantitative Immunofluorescence to Measure Global Localized Translation
Published on: August 22, 2017
Meena Subramanyam1, Jaya Goyal2
1Global Biomarker Discovery and Development, Biogen, 300 Binney St., Cambridge, MA 02142, United States.
Abstract:
The refinement of disease taxonomy utilizing molecular phenotypes has led to significant improvements in the precision of disease diagnosis and customization of treatment options. This has also spurred efforts to identify novel biomarkers to understand the impact of therapeutically altering the underlying molecular network on disease course, and to support decision-making in drug discovery and development. However, gaps in knowledge regarding disease heterogeneity, combined with the inadequacies of surrogate disease model systems, make it challenging to demonstrate the unequivocal association of molecular and physiological biomarkers to disease pathology. This article will discuss the current landscape in biomarker research and highlight strategies being adopted to increase the likelihood of transitioning biomarkers from discovery to medical practice to enable more objective decision making, and to improve health outcome.
Related Concept Videos
Translational Regulation
Leaky Scanning
Pharmacogenomics: Identification of New Drug Targets
Microorganisms in Medicine and Therapeutics
Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...
Improving Translational Accuracy

